Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received an average recommendation of “Buy” from the eleven research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $18.50.

KPTI has been the subject of a number of research analyst reports. Canaccord Genuity set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 8th. BidaskClub upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 9th. Jefferies Group restated a “buy” rating and set a $19.00 price objective (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. ValuEngine cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 18th. Finally, Royal Bank Of Canada initiated coverage on shares of Karyopharm Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $14.00 price objective for the company.

In other news, SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total transaction of $55,777.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the sale, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The disclosure for this sale can be found here. Insiders have sold 13,458 shares of company stock valued at $152,778 in the last ninety days. Insiders own 14.71% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its holdings in shares of Karyopharm Therapeutics by 0.7% during the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock worth $592,000 after buying an additional 308 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Karyopharm Therapeutics by 8.0% in the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares during the period. Schwab Charles Investment Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 4.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock valued at $1,111,000 after purchasing an additional 3,762 shares during the period. Voya Investment Management LLC grew its holdings in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after purchasing an additional 4,444 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after purchasing an additional 5,586 shares during the period. 60.92% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics (NASDAQ KPTI) traded up $0.03 on Friday, hitting $11.19. 226,400 shares of the company traded hands, compared to its average volume of 237,001. Karyopharm Therapeutics has a 1 year low of $7.48 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. research analysts anticipate that Karyopharm Therapeutics will post -2.59 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics Inc. (KPTI) Receives Average Rating of “Buy” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/01/karyopharm-therapeutics-inc-kpti-receives-average-rating-of-buy-from-analysts.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.